Trying to determine the effect of the PR will be t
Post# of 72433
B-OM: Top line results very soon, likely in Nov. Had very promising interim results. If interim results are replicated, the Brilacidin platform should be a lock for a solid deal.
Kevetrin Phase 2A: Cohort A readout in Q4 some time. Could demonstrate nothing or could hint at one of the biggest cancer breakthroughs ever.
Prurisol 2B: Top line results likely in the Dec-Jan area. Higher dosage, easier target population and easier grading metrics than phase 2a. Should result in something between a marketable deal candidate to an absolute blockbuster.
Partnership: If the results of B-OM and Prurisol are good, I would expect a partnership in 2018, probably in the first half. If none of the previously mentioned trial results move the shareprice up significantly, a partnership likely will.
Lots of good trial nuggets coming in the next four months. A deal is also likely in the next 6-12 months. I wouldn't worry too much about how this PR impacts things. Just make sure you have your seat at the IPIX table for when the main course is served.
Go IPIX!
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)